Pinealon is a tripeptide bioregulator (Glu-Asp-Arg) within the wider Khavinson short-peptide bioregulator programme, targeted for pineal-cognitive-relevance research applications. It sits alongside Epitalon in the pineal-tissue-derived research angle but with a distinct chemical structure and mechanism-of-action characterisation.

The compound's research applications have focused primarily on preclinical animal-cognition research contexts — rodent behavioural-endpoint testing across various learning-and-memory paradigms — rather than the extended human-follow-up work that characterises the Epitalon evidence base.

The preclinical evidence base uses standard rodent cognitive-endpoint paradigms including Morris water maze, passive-avoidance testing, novel-object-recognition testing, and 8-arm radial-maze paradigms. Assessments cover both younger and aged animal cohorts to explore cognitive-ageing research applications specifically.

The intervention protocols typically use short-course peripheral administration of Pinealon at microgram-range doses, sometimes across repeated cycles matching the Khavinson bioregulator programme's standard dosing framework. Comparison arms receive vehicle-only control administration.

The consistent finding across the preclinical cognitive-endpoint evidence base is improvement in learning-and-memory endpoints in the Pinealon arm relative to vehicle-control comparisons. Effect magnitudes are moderate rather than dramatic, and the strongest signals typically emerge in aged-animal cohorts where cognitive-decline baseline provides more measurement range.

Mechanistic biomarker data supports the behavioural findings — reduced markers of neuroinflammation and oxidative stress, preserved hippocampal neuronal-population measures, and modulated expression of learning-and-memory-relevant transcripts.

Well-tolerated safety profile in the preclinical evidence base without evidence of significant adverse effects at studied doses.

The preclinical evidence base is animal-only. Pinealon has not been extensively characterised in human cognitive-endpoint clinical trials — the pineal-cognitive-relevance research programme's human evidence base is concentrated in Epitalon rather than Pinealon.

The concentrated single-research-programme origin means independent replication by non-Khavinson-affiliated research groups is limited, restricting the generalisability of the reported effects.

Extrapolation from rodent cognitive-endpoint results to human cognitive-decline contexts requires substantial caution — the relevant mechanism-conservation and pharmacokinetic considerations are non-trivial.

The Pinealon preclinical cognition evidence base is real and provides research-tool motivation for further translational and mechanism work on the compound in cognitive-decline research contexts. It is not, however, strong enough on its own to support human-cognitive-endpoint claims — Pinealon remains a research chemical in the cognitive-application context.

For research purposes the preclinical evidence base provides a credible starting point for further translational-model work and eventual human-cognitive-endpoint characterisation. For clinical purposes Pinealon is not an approved cognitive intervention anywhere and should not be used in that context.